DE60121145T2 - Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln - Google Patents
Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln Download PDFInfo
- Publication number
- DE60121145T2 DE60121145T2 DE60121145T DE60121145T DE60121145T2 DE 60121145 T2 DE60121145 T2 DE 60121145T2 DE 60121145 T DE60121145 T DE 60121145T DE 60121145 T DE60121145 T DE 60121145T DE 60121145 T2 DE60121145 T2 DE 60121145T2
- Authority
- DE
- Germany
- Prior art keywords
- compound
- treatment
- pharmaceutical composition
- malignant
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 38
- 206010028980 Neoplasm Diseases 0.000 title abstract description 22
- -1 RETINOID COMPOUNDS Chemical class 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 96
- 102000014150 Interferons Human genes 0.000 claims abstract description 34
- 108010050904 Interferons Proteins 0.000 claims abstract description 34
- 230000003211 malignant effect Effects 0.000 claims abstract description 25
- 229940079322 interferon Drugs 0.000 claims abstract description 22
- 241000124008 Mammalia Species 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 206010006187 Breast cancer Diseases 0.000 claims description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims description 17
- 229940127089 cytotoxic agent Drugs 0.000 claims description 15
- 102000006992 Interferon-alpha Human genes 0.000 claims description 10
- 108010047761 Interferon-alpha Proteins 0.000 claims description 9
- 108090000467 Interferon-beta Proteins 0.000 claims description 9
- 108010074328 Interferon-gamma Proteins 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 102000003996 Interferon-beta Human genes 0.000 claims description 7
- 102000008070 Interferon-gamma Human genes 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 229960001388 interferon-beta Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 22
- 230000002195 synergetic effect Effects 0.000 abstract description 19
- 239000000556 agonist Substances 0.000 abstract description 6
- 101001100204 Homo sapiens Ras-related protein Rab-40A-like Proteins 0.000 abstract 1
- 102100038416 Ras-related protein Rab-40A-like Human genes 0.000 abstract 1
- 101100236975 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GAL11 gene Proteins 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 description 36
- 238000003556 assay Methods 0.000 description 33
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 30
- 108091008726 retinoic acid receptors α Proteins 0.000 description 30
- PNAWUIKCVQSLFG-UHFFFAOYSA-N 4-[(4-chloro-3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]-2,6-difluorobenzoic acid Chemical compound C1=C2C(C)(C)CCC(C)(C)C2=C(Cl)C(O)=C1C(=O)NC1=CC(F)=C(C(O)=O)C(F)=C1 PNAWUIKCVQSLFG-UHFFFAOYSA-N 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 229940047124 interferons Drugs 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000000996 additive effect Effects 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 108091008760 retinoic acid receptors γ Proteins 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 102100038595 Estrogen receptor Human genes 0.000 description 5
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
- 108010038795 estrogen receptors Proteins 0.000 description 5
- 229940044627 gamma-interferon Drugs 0.000 description 5
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 5
- 102000003702 retinoic acid receptors Human genes 0.000 description 5
- 108090000064 retinoic acid receptors Proteins 0.000 description 5
- 108091008761 retinoic acid receptors β Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 108010038912 Retinoid X Receptors Proteins 0.000 description 4
- 102000034527 Retinoid X Receptors Human genes 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 4
- 238000000670 ligand binding assay Methods 0.000 description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- BCKLKOYFMACAMZ-UHFFFAOYSA-N 2,6-difluoro-4-[(3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]benzoic acid Chemical compound OC=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(=O)NC1=CC(F)=C(C(O)=O)C(F)=C1 BCKLKOYFMACAMZ-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 239000003637 basic solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- FPHBAXANDIFPKG-UHFFFAOYSA-N ethyl 2,6-difluoro-4-[(3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]benzoate Chemical compound C1=C(F)C(C(=O)OCC)=C(F)C=C1NC(=O)C1=CC(C(CCC2(C)C)(C)C)=C2C=C1O FPHBAXANDIFPKG-UHFFFAOYSA-N 0.000 description 2
- AGVFJTCMRKAWMC-UHFFFAOYSA-N ethyl 4-[(4-chloro-3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]-2,6-difluorobenzoate Chemical compound C1=C(F)C(C(=O)OCC)=C(F)C=C1NC(=O)C1=CC(C(CCC2(C)C)(C)C)=C2C(Cl)=C1O AGVFJTCMRKAWMC-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- LCRXHDFRVSNAHW-UHFFFAOYSA-N methyl 2,6-difluoro-4-[[3-(methoxymethoxy)-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl]amino]benzoate Chemical compound COCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=O)NC1=CC(F)=C(C(=O)OC)C(F)=C1 LCRXHDFRVSNAHW-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 230000030541 receptor transactivation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102000027483 retinoid hormone receptors Human genes 0.000 description 2
- 108091008679 retinoid hormone receptors Proteins 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- VGMGQJOQTUARPK-UHFFFAOYSA-N 3-(methoxymethoxy)-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carboxylic acid Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(O)=O)C(OCOC)=C2 VGMGQJOQTUARPK-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 0 CC(C)(CCC(C)(C)c1c2Cl)c1cc(C(Nc1cc(F)c(*)c(F)c1)=O)c2O Chemical compound CC(C)(CCC(C)(C)c1c2Cl)c1cc(C(Nc1cc(F)c(*)c(F)c1)=O)c2O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000640876 Homo sapiens Retinoic acid receptor RXR-beta Proteins 0.000 description 1
- 101000640882 Homo sapiens Retinoic acid receptor RXR-gamma Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100034253 Retinoic acid receptor RXR-beta Human genes 0.000 description 1
- 102100034262 Retinoic acid receptor RXR-gamma Human genes 0.000 description 1
- 108010066463 Retinoid X Receptor alpha Proteins 0.000 description 1
- 102000026043 Retinoid X Receptor alpha Human genes 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- UWPLTCWTTVMXCM-UHFFFAOYSA-N methyl 4-amino-2,6-difluorobenzoate Chemical compound COC(=O)C1=C(F)C=C(N)C=C1F UWPLTCWTTVMXCM-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000001403 relative X-ray reflectometry Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 102000027478 retinoid receptor subtypes Human genes 0.000 description 1
- 108091008678 retinoid receptor subtypes Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54214800A | 2000-04-04 | 2000-04-04 | |
| US542148 | 2000-04-04 | ||
| PCT/US2001/010410 WO2001074759A1 (en) | 2000-04-04 | 2001-04-02 | Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60121145D1 DE60121145D1 (de) | 2006-08-10 |
| DE60121145T2 true DE60121145T2 (de) | 2007-05-31 |
Family
ID=24162539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60121145T Expired - Lifetime DE60121145T2 (de) | 2000-04-04 | 2001-04-02 | Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6387950B2 (enExample) |
| EP (2) | EP1650188A1 (enExample) |
| JP (1) | JP2003534246A (enExample) |
| AT (1) | ATE331703T1 (enExample) |
| AU (1) | AU2001253045A1 (enExample) |
| CA (1) | CA2405136C (enExample) |
| DE (1) | DE60121145T2 (enExample) |
| ES (1) | ES2267754T3 (enExample) |
| TW (1) | TWI281911B (enExample) |
| WO (1) | WO2001074759A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6903121B1 (en) | 2000-08-17 | 2005-06-07 | Allergan, Inc. | Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents |
| HU230063B1 (hu) * | 2000-10-02 | 2015-06-29 | Hoffmann La Roche | Retinoidok emfizéma kezelésére |
| EP1935869A1 (en) * | 2000-10-02 | 2008-06-25 | F. Hoffmann-La Roche Ag | Retinoids for the treatment of emphysema |
| US6620963B1 (en) | 2002-09-19 | 2003-09-16 | Allergan, Inc. | TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY |
| WO2005093426A2 (en) * | 2004-03-26 | 2005-10-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara) |
| DK1937244T3 (en) | 2005-09-30 | 2018-10-29 | Io Therapeutics Llc | : CANCER TREATMENT WITH SPECIFIC RXR AGONISTS |
| WO2012125749A2 (en) * | 2011-03-14 | 2012-09-20 | Io Therapeutics, Inc. | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS |
| CN104114171A (zh) | 2011-12-13 | 2014-10-22 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| ES2901792T3 (es) | 2015-03-31 | 2022-03-23 | Syros Pharmaceuticals Inc | Procedimientos de estratificación de pacientes para el tratamiento con agonistas del receptor del ácido retinoico |
| MX364892B (es) | 2015-10-31 | 2019-05-10 | Io Therapeutics Inc | Tratamiento de trastornos del sistema nervioso utilizando combinaciones de agonistas de rxr y hormonas tiroideas. |
| PL3380086T3 (pl) * | 2015-11-25 | 2022-02-21 | Io Therapeutics, Inc. | Oporne na cyp26 agonisty selektywne względem rar-alfa w leczeniu nowotworu |
| EP3426302B1 (en) | 2016-03-10 | 2022-12-14 | IO Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones |
| DK3426303T3 (da) | 2016-03-10 | 2022-09-19 | Io Therapeutics Inc | Behandling af muskellidelser med kombinationer af rxr-agonister og thyroideahormoner |
| CN115737821B (zh) | 2016-04-08 | 2024-04-12 | 赛罗斯制药有限公司 | 用于治疗aml和mds的rara激动剂 |
| US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
| WO2019014492A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RETINOID COMPOUNDS AND IMMUNOMODULATORY REXINOIDS IN COMBINATION WITH IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER |
| KR20200044889A (ko) | 2017-08-31 | 2020-04-29 | 아이오 테라퓨틱스, 인크. | 암 면역요법을 위해 면역 조절제와 조합된 rar 선택적 작용제 |
| EP3684348A4 (en) | 2017-09-20 | 2021-08-18 | IO Therapeutics, Inc. | TREATMENT OF DISEASE WITH SELECTIVE RXR AGONIST ESTERS |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| JP2024543621A (ja) | 2021-12-07 | 2024-11-21 | アイオー セラピューティクス インコーポレイテッド | Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストおよびタキサンの使用 |
| WO2023108015A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist in treating drug resistant her2+ cancers |
| CN114703227B (zh) * | 2022-01-27 | 2023-11-10 | 中国科学院生态环境研究中心 | 基于MCF-7细胞系构建的RARα效应物体外筛选方法 |
| KR20250029925A (ko) | 2022-06-27 | 2025-03-05 | 아이오 테라퓨틱스, 인크. | 테트라히드로나프탈레놀의 합성 및 그의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2123223C (en) | 1991-12-18 | 2001-10-09 | Ronald M. Evans | Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor |
| US5675024A (en) * | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
| US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
-
2001
- 2001-03-30 TW TW090107695A patent/TWI281911B/zh not_active IP Right Cessation
- 2001-04-02 CA CA002405136A patent/CA2405136C/en not_active Expired - Lifetime
- 2001-04-02 EP EP05025970A patent/EP1650188A1/en not_active Withdrawn
- 2001-04-02 WO PCT/US2001/010410 patent/WO2001074759A1/en not_active Ceased
- 2001-04-02 EP EP01926512A patent/EP1268405B1/en not_active Expired - Lifetime
- 2001-04-02 DE DE60121145T patent/DE60121145T2/de not_active Expired - Lifetime
- 2001-04-02 AT AT01926512T patent/ATE331703T1/de not_active IP Right Cessation
- 2001-04-02 AU AU2001253045A patent/AU2001253045A1/en not_active Abandoned
- 2001-04-02 ES ES01926512T patent/ES2267754T3/es not_active Expired - Lifetime
- 2001-04-02 US US09/824,111 patent/US6387950B2/en not_active Expired - Fee Related
- 2001-04-02 JP JP2001572454A patent/JP2003534246A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI281911B (en) | 2007-06-01 |
| DE60121145D1 (de) | 2006-08-10 |
| US6387950B2 (en) | 2002-05-14 |
| EP1650188A1 (en) | 2006-04-26 |
| CA2405136C (en) | 2009-06-16 |
| US20010039293A1 (en) | 2001-11-08 |
| EP1268405B1 (en) | 2006-06-28 |
| ATE331703T1 (de) | 2006-07-15 |
| ES2267754T3 (es) | 2007-03-16 |
| WO2001074759A1 (en) | 2001-10-11 |
| JP2003534246A (ja) | 2003-11-18 |
| AU2001253045A1 (en) | 2001-10-15 |
| EP1268405A1 (en) | 2003-01-02 |
| CA2405136A1 (en) | 2001-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60121145T2 (de) | Behandlung von tumoren mit rar alpha selektiven retinoid-verbindungen zusammen mitanderen antitumormitteln | |
| DE69633679T2 (de) | Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität | |
| DE60208397T2 (de) | Valproinsäure zur Behandlung von Brustkrebs, Dickdarmkrebs, Kopf-Hals-Krebs, kleinzelligem Lungenkarzinom und Blutzellenkrebs in Kombination mit Bestrahlung | |
| DE60129960T2 (de) | Benzamidliganden für den thyroid-rezeptor | |
| DE69618600T2 (de) | Colchicine derivate, deren verwendung und sie enthaltende formulierungen | |
| DE69328910T2 (de) | Verwendung von 9-cis-Retinsäure sowie ihre Salze und Ester, zur Behandlung von Epitheltumore | |
| DE69327255T2 (de) | Selektivitaet fuer retinoid x rezeptoren enthaltende verbindungen | |
| DE69936397T2 (de) | 3,4-disubstituierte acylanilidderivate und deren verwendung als androgen rezeptor suppressoren | |
| DE60110753T2 (de) | Thyroid-rezeptorliganden, die von anilin ableitbar sind | |
| EP0708640B1 (de) | Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält | |
| DE69631975T2 (de) | Discodermolide verbindungen und deren pharmazeutische zusammensetzungen zur krebstherapie | |
| DE69530933T2 (de) | Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis | |
| DE69019533T2 (de) | Behandlung von hiv-infizierungen und nützliche verbindungen dafür. | |
| DE3887793T2 (de) | 5-Amino- oder substituierte Amino-1,2,3-Triazole, verwendbar als Antiproliferativa. | |
| DE69604713T2 (de) | Retinoide | |
| DE112007003375B4 (de) | Imidazolderivate, die Apoptose induzieren, und deren therapeutische Anwendung | |
| DE69724127T2 (de) | Substituierte benzyliden-indenyl-formamide, acetamide und propionamide | |
| DE69528103T2 (de) | Verwendung von Riminophenazin zur Behandlung von MDR-Resistenz | |
| DE10038007A1 (de) | Neue Amino-und Amido-Diphenylether für Arzneimittel | |
| DE69623595T2 (de) | Verfahren zur behandlung hyperproliferativer epithel-läsionen durch topische verabreichung von hydroxylierten aromatischen protein-crosslinking verbindungen | |
| DE2519394A1 (de) | Mittel zur behandlung von virusinfektionen | |
| DE69927710T2 (de) | Phenethyl-5-bromopyridylthioharnstoff (pbt) derivative mit spermizider wirkung | |
| DE69905877T2 (de) | Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen | |
| DE19523079A1 (de) | Ester und Amide der 9(Z)-Retinsäure | |
| DE3686729T2 (de) | Aminoalkylpyridinamide. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |